- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03049384
Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background and Rationale
Approximately one-third of cancer survivors experience severe and persistent fatigue for a number of years post-treatment, but this distressing symptom is often under-treated by healthcare professionals due to a lack of mechanism-targeted interventions. The assessment of cancer-related fatigue (CRF) is reliant on subjective fatigue measurements such as self-report questionnaires. Less attention has been given to objective physiological measurements. However, there are well-established techniques which allow the assessment of neuromuscular fatigue and its peripheral and central origins which could be utilized in the study of CRF. Very few studies have considered these objective measures alongside self-report scales in the study of CRF and only two have used such techniques in cancer survivors. To date, no studies have investigated neuromuscular fatigue in whole body, dynamic activity as relevant to daily tasks (and involving the lower limb due to its functional relevance to locomotion). Novel testing developed in our laboratory could be used as part of a wider screening to develop individualized interventions to alleviate CRF. It is well accepted in the field that CRF is multidimensional and in addition to a potential neuromuscular component, the role of sleep disturbance may also be implicated. Interventions targeted at improving sleep quality are therefore warranted, and there is sound evidence for the efficacy of exercise interventions in particular for improving CRF in cancer survivors. As a non-pharmacological intervention, physical activity has the strongest evidence base for treating CRF. However, the mechanisms explaining the reduction of CRF with exercise are not understood. Due to the complex and multi-factorial nature of CRF, it would be of benefit to tailor exercise interventions to the specific deficits (in regards to neuromuscular mechanisms) or difficulties (for example sleep disturbance) experienced by the individual. Ultimately, mechanism-targeted exercise interventions could be translated to clinical rehabilitation programs and lead to an improved quality of for cancer survivors.
Research Question & Objectives
The primary aim of this research is to investigate the effect of a traditional vs. tailored 12-week exercise intervention on self-reported CRF severity.
Methods
Fatigued cancer survivors who have completed primary treatment ≥ 3 months and ≤ 5 years from enrollment will be randomly allocated to one of two treatment arms: traditional (active control) and tailored exercise. Participants in the traditional exercise group will engage in aerobic and resistance exercise that is consistent with published recommendations. The tailored exercise group will be prescribed an intervention designed to address individual deficits (identified at baseline) that may be related to CRF. Participants will be assessed before and after the intervention for patient-reported outcomes, neuromuscular function and fatigue in response to whole-body exercise, sleep quantity and quality, physical activity levels, cardiorespiratory fitness and blood biomarkers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- University of Calgary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 75 years;
- Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score ≤ 34;
- Completion of treatment in ≥ 3 months and ≤ 5 years preceding enrollment;
- Approval received from personal physician and/or a Canadian Society for Exercise Physiology-Clinical Exercise Physiologist (CSEP-CEP);
- Command of the English language.
Exclusion Criteria:
- Contraindication to experimental procedures including transcranial magnetic stimulation (TMS);
- Diagnosed as having obstructive sleep apnea or anemia;
- Currently participating in a structured exercise intervention;
- Participant is pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Traditional Exercise
A classical exercise intervention based on current guidelines for cancer survivors.
|
The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
|
Experimental: Tailored Exercise
A tailored and individualized exercise intervention based on the results of pre-intervention testing.
|
The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g.
neuromuscular) of difficulties (e.g.
sleep disturbance) identified during pre-intervention testing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Scale
Time Frame: Baseline to after the 12-week intervention, at 6 month and 12 month follow up.
|
Self-report questionnaire for the assessment of cancer-related fatigue.
|
Baseline to after the 12-week intervention, at 6 month and 12 month follow up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change in The Functional Assessment of Cancer Therapy - General (FACT-G)
Time Frame: Baseline and after the 12-week intervention.
|
General quality of life instrument intended for use with a variety of chronic illness conditions.
|
Baseline and after the 12-week intervention.
|
Assessment of change in Edmonton Symptom Assessment System-revised tiredness scale
Time Frame: Baseline and after the 12-week intervention, and during follow up (6 and 12 months).
|
Self-report questionnaire for the assessment of of nine common symptoms experienced by cancer patients.
|
Baseline and after the 12-week intervention, and during follow up (6 and 12 months).
|
Maximal Isometric Force in the Knee Extensors
Time Frame: Baseline and after the 12-week intervention.
|
A reduction in maximal isometric force in the knee extensors measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Cortical Voluntary Activation
Time Frame: Baseline and after the 12-week intervention.
|
A reduction voluntary activation (using transcranial magnetic stimulation) measured measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Voluntary Activation
Time Frame: Baseline and after the 12-week intervention.
|
A reduction voluntary activation (using femoral nerve stimulation) measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Potentiated Doublet Twitch Force
Time Frame: Baseline and after the 12-week intervention.
|
A reduction in potentiated quadriceps twitch force (from a high frequency doublet at 100 Hz) measured before, before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Muscle Compound Action Potential (M-Wave) Peak-to Peak Amplitude
Time Frame: Baseline and after the 12-week intervention.
|
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Muscle Compound Action Potential (M-Wave) Peak-to Peak Duration
Time Frame: Baseline and after the 12-week intervention.
|
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Muscle Compound Action Potential (M-Wave) Area
Time Frame: Baseline and after the 12-week intervention.
|
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Motor Evoked Potential (MEP) Peak-to Peak Amplitude
Time Frame: Baseline and after the 12-week intervention.
|
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Motor Evoked Potential (MEP) Peak-to Peak Duration
Time Frame: Baseline and after the 12-week intervention.
|
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Motor Evoked Potential (MEP) Area
Time Frame: Baseline and after the 12-week intervention.
|
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Cortical Silent Period
Time Frame: Baseline and after the 12-week intervention.
|
Evoked from TMS and measured (from stimulation artifact to the continuous resumption of EMG) before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Voluntary Electromyography (EMG)
Time Frame: Baseline and after the 12-week intervention.
|
Root mean square of the EMG signal during an MVC, measured before, during and after an intermittent cycling test.
|
Baseline and after the 12-week intervention.
|
Amplitude of the Sleep-Wake Cycle
Time Frame: Baseline and after the 12-week intervention.
|
The mean difference between lowest and highest activity period, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Peak Time of the sleep-wake Cycle
Time Frame: Baseline and after the 12-week intervention.
|
Time of day of the highest estimated level of wake, recorded by actigraphy.
|
Baseline and after the 12-week intervention.
|
Mesor of the Sleep-Wake Cycle
Time Frame: Baseline and after the 12-week intervention.
|
Mean level of activity over 24 hours, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
inter-daily stability
Time Frame: Baseline and after the 12-week intervention.
|
the degree of regularity of the rest-activity patterns on individual days in the 24 h environment, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
intra-daily variability
Time Frame: Baseline and after the 12-week intervention.
|
the fragmentation of periods of rest and activity, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
L5
Time Frame: Baseline and after the 12-week intervention.
|
The mean activity counts in the least active 5 h period in the average 24 h pattern) recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
L5 mid
Time Frame: Baseline and after the 12-week intervention.
|
The central time of the L5 period, usually referring to the through of the activity period), recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Wake actigraphy
Time Frame: Baseline and after the 12-week intervention.
|
Amount of activity during wake, recorded with actigraphy
|
Baseline and after the 12-week intervention.
|
Sleep Activity
Time Frame: Baseline and after the 12-week intervention.
|
Amount of activity during sleep periods, recorded with actigraphy
|
Baseline and after the 12-week intervention.
|
Activity Index
Time Frame: Baseline and after the 12-week intervention.
|
Percentage of activity per epoch for wake and sleep, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Time in bed
Time Frame: Baseline and after the 12-week intervention.
|
Time spent between the moment subject turn off the light to sleep and the moment he gets up, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Actual Sleep Time
Time Frame: Baseline and after the 12-week intervention.
|
Time spent asleep during the night, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Actual Wake Time
Time Frame: Baseline and after the 12-week intervention.
|
Time spent awaken during the night, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Sleep Onset Latency
Time Frame: Baseline and after the 12-week intervention.
|
Time to fall asleep, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Sleep Efficiency
Time Frame: Baseline and after the 12-week intervention.
|
Ratio between the time spent asleep and the total duration of sleep period, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Fragmentation index
Time Frame: Baseline and after the 12-week intervention.
|
Indication of the sleep quality based on movement during night, recorded with actigraphy.
|
Baseline and after the 12-week intervention.
|
Blood Biomarkers
Time Frame: Baseline and after the 12-week intervention.
|
Blood count, catecholamines, serotonin, cortisol, inflammatory markers and markers of oxidative stress.
|
Baseline and after the 12-week intervention.
|
Assessment of change in the Centre for Epidemiological Studies Depression Scale (CES-D) questionnaire.
Time Frame: Baseline and after the 12-week intervention.
|
Self-report questionnaire for the assessment of health-related quality of life, specific to cancer type.
|
Baseline and after the 12-week intervention.
|
Assessment of change in The Social Prevision Scale (SPS)
Time Frame: Baseline and after the 12-week intervention.
|
Self-report questionnaire for the assessment of social support.
|
Baseline and after the 12-week intervention.
|
Assessment of change in The Functional Assessment of Cancer Therapy (FACT) Cancer Specific
Time Frame: Baseline and after the 12-week intervention.
|
Self-report questionnaire for the assessment
|
Baseline and after the 12-week intervention.
|
Assessment of change in The Modified-Godin Leisure Time Exercise Questionnaire (GLTEQ)
Time Frame: Baseline, after the 12-week intervention, and during follow up (6 and 12 months).
|
Self-report questionnaire for the assessment of leisure time physical activity.
|
Baseline, after the 12-week intervention, and during follow up (6 and 12 months).
|
Assessment of change in The Insomnia Severity Index (ISI)
Time Frame: Baseline and after the 12-week intervention.
|
Self-report questionnaire for the assessment of insomnia severity.
|
Baseline and after the 12-week intervention.
|
Assessment of change in The Brief Pain Inventory Short Form (BPI-sf)
Time Frame: Baseline and after the 12-week intervention.
|
Self-report questionnaire for the assessment of pain.
|
Baseline and after the 12-week intervention.
|
Assessment of change in Maximal Oxygen Uptake
Time Frame: Baseline and after the 12-week intervention.
|
The highest 30 second average oxygen uptake measured during an an incremental cycling test.
|
Baseline and after the 12-week intervention.
|
Assessment of change in Muscle Cross-Sectional Area
Time Frame: Baseline and after the 12-week intervention.
|
Ultrasound measurement of the vastus lateralis and rectus femoris.
|
Baseline and after the 12-week intervention.
|
Heart Rate Variability
Time Frame: Baseline and after the 12-week intervention.
|
Variation in the time interval between heartbeats.
|
Baseline and after the 12-week intervention.
|
Assessment of change in Fat Mass
Time Frame: Baseline and after the 12-week intervention.
|
Measured using dual energy X-ray absorptiometry (DXA).
|
Baseline and after the 12-week intervention.
|
Assessment of change in Fat Free Mass
Time Frame: Baseline and after the 12-week intervention.
|
Measured using dual energy X-ray absorptiometry (DXA).
|
Baseline and after the 12-week intervention.
|
Assessment of change in Bone Mineral Density
Time Frame: Baseline and after the 12-week intervention.
|
Measured using dual energy X-ray absorptiometry (DXA).
|
Baseline and after the 12-week intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Guillaume Millet, PhD, University of Calgary
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HREBA.CC-16-1010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer-related Fatigue
-
Buddhist Tzu Chi General HospitalRecruitingGynecologic Cancer | Cancer-related FatigueTaiwan
-
Taipei Medical UniversityNot yet recruitingCancer Related Fatigue
-
German Cancer Research CenterNational Center for Tumor Diseases, HeidelbergRecruitingCancer-related FatigueGermany
-
German Cancer Research CenterGerman Research Foundation; Wuerzburg University Hospital; Baden-Württemberg...RecruitingCancer-related FatigueGermany
-
Taichung Tzu Chi HospitalNot yet recruitingCancer-related Fatigue
-
German Cancer Research CenterUniversity Hospital HeidelbergWithdrawnCancer-related Fatigue
-
UConn HealthSusan G. Komen Breast Cancer Foundation; Hollfelder foundationTerminatedCancer-related FatigueUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Center for Complementary and Integrative...CompletedCancer Related FatigueUnited States
-
National Cancer Center, KoreaSamsung Medical Center; Seoul National University Hospital; Korea University...UnknownCancer-related FatigueKorea, Republic of
-
PhytoHealth CorporationCompletedCancer-related FatigueTaiwan
Clinical Trials on Traditional Exercise
-
October 6 UniversityCompleted
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
Norwegian University of Science and TechnologyCompletedDiabetes Mellitus, Type 2Norway
-
Saglik Bilimleri UniversitesiRecruiting
-
Catholic University of the Sacred HeartCompletedShoulder Impingement SyndromeItaly
-
Cairo UniversityCompleted
-
Cairo UniversityRecruiting
-
Superior UniversityRecruiting
-
University of Alberta, Physical EducationCompletedSedentary Behaviour | Adherence | Traditional Exercise | Lifestyle ExerciseCanada
-
VA Office of Research and DevelopmentRecruiting